TY - GEN
T1 - 'HyperShear in a channel'
T2 - 2014 IEEE Healthcare Innovation Conference, HIC 2014
AU - Dimasi, A.
AU - Redaelli, A.
AU - Bluestein, D.
AU - Rasponi, M.
AU - Slepian, Marvin J
N1 - Publisher Copyright:
© 2014 IEEE.
PY - 2014/2/10
Y1 - 2014/2/10
N2 - Thrombosis of ventricular assist devices is a significant complication compromising device efficacy with attendant risks of systemic embolization, stroke, pump stop and death. Presently anti-thrombotic therapy is utilized to mitigate thrombotic risk. Drugs such as aspirin and dipyridamole are largely dosed empirically, without individualized testing of efficacy in a given patient. To date testing systems available for examining anti-platelet agent efficacy are limited in that they are largely central lab-based and typically examine drug efficacy under conditions that do not represent the flow and shear conditions of the patient during actual VAD use. In the present paper we adopt a technology, Device Thrombogenicity Emulation - a methodology developed by our group which characterizes the actual shear stress history experienced by platelets in a blood recirculating device, i.e. total exposure level, individual platelet flight trajectories - and utilize this to create a facsimile of the shear stress profile of a ventricular assist device in a small footprint microfluidic channel point-of-care system. Creating a device-specific microfluidic facsimile will allow the development of a point-of-care testing system reflective of an actual device in a given patient. This will afford determination of anti-thrombotic agent efficacy under personalized conditions, reducing the likelihood of VAD thrombosis, increasing overall patient safety.
AB - Thrombosis of ventricular assist devices is a significant complication compromising device efficacy with attendant risks of systemic embolization, stroke, pump stop and death. Presently anti-thrombotic therapy is utilized to mitigate thrombotic risk. Drugs such as aspirin and dipyridamole are largely dosed empirically, without individualized testing of efficacy in a given patient. To date testing systems available for examining anti-platelet agent efficacy are limited in that they are largely central lab-based and typically examine drug efficacy under conditions that do not represent the flow and shear conditions of the patient during actual VAD use. In the present paper we adopt a technology, Device Thrombogenicity Emulation - a methodology developed by our group which characterizes the actual shear stress history experienced by platelets in a blood recirculating device, i.e. total exposure level, individual platelet flight trajectories - and utilize this to create a facsimile of the shear stress profile of a ventricular assist device in a small footprint microfluidic channel point-of-care system. Creating a device-specific microfluidic facsimile will allow the development of a point-of-care testing system reflective of an actual device in a given patient. This will afford determination of anti-thrombotic agent efficacy under personalized conditions, reducing the likelihood of VAD thrombosis, increasing overall patient safety.
UR - http://www.scopus.com/inward/record.url?scp=84949923207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949923207&partnerID=8YFLogxK
U2 - 10.1109/HIC.2014.7038863
DO - 10.1109/HIC.2014.7038863
M3 - Conference contribution
AN - SCOPUS:84949923207
T3 - 2014 IEEE Healthcare Innovation Conference, HIC 2014
SP - 14
EP - 17
BT - 2014 IEEE Healthcare Innovation Conference, HIC 2014
PB - Institute of Electrical and Electronics Engineers Inc.
Y2 - 8 October 2014 through 10 October 2014
ER -